Clinical Trial Update: LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study (LEGEND Study: EG-70) is recruiting to evaluate EG-70 in non-muscle invasive bladder cancer, including patients with carcinoma in situ who are…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Carcinoma in Situ of the Bladder
• Non-muscle Invasive Bladder Cancer

Drugs mentioned

• EG-70

Snippet

Sponsor: enGene, Inc. | Conditions: Superficial Bladder Cancer, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ | Phase 1, Phase 2 | Status: RECRUITING